Benzinga | Jan 19, 2021 08:03AM EST

Royalty Pharma To Acquire Minerva Neurosciences' Seltorexant Royalty Interest For Upfront Payment Of $60M And Up To $95M In Milestone Payments

WALTHAM, Mass. and NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV) and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will acquire Minerva's royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments. The additional payments to Minerva will be contingent on the achievement of certain clinical, regulatory and commercialization milestones.